BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15530639)

  • 1. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
    Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
    Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
    Esbenshade TA; Fox GB; Cowart MD
    Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
    Onodera K; Watanabe T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3 receptor antagonists/inverse agonists as anti-obesity agents.
    Hancock AA
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine H3 receptors and sleep-wake regulation.
    Lin JS; Sergeeva OA; Haas HL
    J Pharmacol Exp Ther; 2011 Jan; 336(1):17-23. PubMed ID: 20864502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The histamine H(3) receptor: a target for new drugs].
    Arrang JM
    Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
    Chazot PL; Hann V
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1428-31. PubMed ID: 11890359
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
    Witkin JM; Nelson DL
    Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine H3 receptor as a drug discovery target.
    Berlin M; Boyce CW; Ruiz Mde L
    J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
    [No Abstract]   [Full Text] [Related]  

  • 14. Histamine H3 and H4 receptors as novel drug targets.
    Tiligada E; Zampeli E; Sander K; Stark H
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of histamine H3 receptor agonists and antagonists.
    Leurs R; Blandina P; Tedford C; Timmerman H
    Trends Pharmacol Sci; 1998 May; 19(5):177-83. PubMed ID: 9652190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers.
    Schnell D; Burleigh K; Trick J; Seifert R
    J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
    Leurs R; Bakker RA; Timmerman H; de Esch IJ
    Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The histamine H3 receptor: a new target for the treatment of arousal and cognitive disorders].
    Arrang JM
    Ann Pharm Fr; 2007 Jul; 65(4):275-84. PubMed ID: 17652997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
    Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.